Use of oral vancomycin in children with autoimmune liver disease: A single centre experience

doi:10.4254/wjh.v13.i12.2113

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4344)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

316

WORD

HTML

2165

Figures (1-2)

276

Tables (1-4)

303

Sum=3152

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

391

Download

801

Sum=1192

Dec 27, 2021 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Dec 27, 2021; 13(12): 2113-2127
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113

Table 1 Laboratory and histological features at diagnosis of 75 children with autoimmune liver disease

	All patients, n = 75	AIH, n = 54	ASC, n = 21	P value
Biochemical profile
AST U/L (NV ≤ 45)	438 (129-982)	678 (204-1200)	150 (94-333)	< 0.001
GGT U/L (NV ≤ 50)	116 (60-296)	107 (54-196)	360 (68-607)	< 0.001
Total bilirubin (NV ≤ 1 mg/dL)	1.7 (0.6-4.5)	2.7 (0.6-5.3)	1.2 (0.7-2.5)	0.05
ALP (NV ≤ 350 U/L)	296 (204-469)	283 (199-462)	301 (242-494)	0.328
ALP/AST ratio	0.7 (0.3-2.2)	0.4 (0.2-1.6)	2.3 (0.7-3.5)	0.002
Albumin (NV: 30-50 g/dL)	42 (38-44)	42 (37-44)	42 (40-46)	0.082
INR (NV: 0.9-1.2)	1.2 (1.1-1.5)	1.2 (1.1-1.6)	1.1 (1.0-1.2)	< 0.05
Platelet (10⁹/L)	252 (180-350)	234 (167-314)	319 (251-393)	< 0.05
Autoimmune profile
ANA (≥ 1:20): n (%)	55 (73)	38 (70)	17 (81)	0.777
SMA (≥ 1:20): n (%)	53 (71)	38 (70)	15 (71)	1
Anti-LKM-1 (≥ 1:10): n (%)	12 (16)	12 (22)	0 (0)	< 0.05
Anti-LC1: n (%)	9 (12)	9 (17)	0 (0)	< 0.05
ANCA: n (%)	37 (49)	22 (41)	15 (71)	< 0.05
IgG g/dL (NV: 0.5-1.8 g/dL)	2.0 (1.4-3.2)	2.3 (1.4-3.3)	1.7 (1.5-2.2)	0.325
IgG > ULN: n (%)	51 (68)	37 (69)	14 (67)	1
Histology, n (%)
Interface hepatitis	51 (68)	42 (78)	12 (57)	0.09
Fibrosis	61 (81)	42 (78)	19 (90)	0.324
Cirrhosis	17 (23)	15 (28)	2 (10)	0.127
Features of biliopathy¹	62 (83)	37 (68)	17 (81)	0.764

¹It includes at least one of the following: inflammatory injury of the bile duct, ductular reaction, periductular fibrosis, biliary metaplasia, granulomatous cholangitis[16]. Values are expressed as median and interquartile ranges.

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; INR: International normalized ratio; ANA: Antinuclear antibody; SMA: Smooth muscle antibody; LKM-1: Liver-kidney microsome antibody type 1; LC1: Liver cytosol antibody type 1; SLA: Liver soluble antigen; ANCA: Anti-neutrophil cytoplasmic LT antibodies; ULN: Upper limit of normal; NV: Normal value.

Table 2 Response to medical treatment and outcome of 75 patients with autoimmune liver diseases

Variables	All patients, n = 75	AIH, n = 54	ASC, n = 21	P value
Treatment, n
Prednisone alone	26 (35%)	19 (35%)	7 (33%)	1
Prednisone + Azathioprine	30 (40%)	28 (52%)	2 (10%)	< 0.001
Prednisone + MMF	5 (7%)	3 (5%)	2 (10%)	0.615
Prednisone + Vancomycin	4 (5%)	1 (2%)	3 (14%)	0.064
Prednisone + Azathioprine + Vancomycin	2 (3%)	0 (0%)	2 (10%)	0.075
Prednisone + MMF + Vancomycin	6 (8%)	1 (2%)	5 (23%)	0.005
Prednisone + Tacrolimus	1 (1%)	1 (2%)	0	NA
Cyclosporine	1 (1%)	1 (2%)	0	NA
Response to treatment
Normal AST (NV ≤ 45 U/L): n	69 (92%)	52 (96%)	17 (81%)	0.048
Time to normalize AST (yr)	0.1 (0.1-0.5)	0.2 (0.1-0.6)	0.1 (0.1-0.2)	0.19
GGT (< 50 UI/L), n	68 (91%)	51 (94%)	17 (81%)	0.811
Time to normalize GGT (yr)	0.3 (0.2-0.6)	0.3 (0.2-0.5)	0.3 (0.2-1.1)	0.062
Immunological remission¹: n	25 (33%)	22 (40%)	3 (14%)	0.032
Time to immunological remission	3.1 (2.2-4.2)	3.8 (2.9-4.3)	3.4 (3.2-3.7)	0.86
Relapse of AILD during treatment, n
At least one relapse	36 (48%)	22 (41%)	14 (67%)	< 0.070
1 relapse alone	26 (35%)	17 (31%)	9 (43%)	0.421
≥ 2 relapses	10 (13%)	5 (9%)	5 (24%)	0.131
Outcome at last follow up
Median follow up, yr (range)	4.4 (0.6-13.8)	4.1 (1.2-11.7)	4.5 (0.6-13.8)	0.079
Alive	75 (100%)	54 (100%)	21 (100%)	NA
OFF-IS therapy	6 (8%)	5 (9%)	1 (5%)	0.666
Medical treatment	68 (91%)	49 (91%)	19 (90%)	1
Liver transplant	1 (1%)	0 (0%)	1 (5%)	0.28

¹Normal aspartate aminotransferase, normal IgG, and negative or low titer autoantibodies.

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; AST: Aspartate aminotransferase; MMF: Mycophenolate mofetil; GGT: Gamma-glutamyl transferase; IS: Immunosuppressive; NA: Not applicable; ALID: Autoimmune liver disease; NV: Normal value.

Table 3 Demographic, biochemical and histological features of 12 patients with autoimmune liver disease treated with oral vancomycin

Patients/ diagnosis	Gender	Age at diagnosis (yr)	Type of presentation	IBD	Splenomegaly¹	IgG > ULN	Auto-antibodies	Histology				Medications
Patients/ diagnosis	Gender	Age at diagnosis (yr)	Type of presentation	IBD	Splenomegaly¹	IgG > ULN	Auto-antibodies	Interface hepatitis	Fibrosis	Cirrhosis	Biliopathy³	Medications
AIH	F	4.2	Asymptomatic	IC	Not	Yes	SMA 1:40; p-ANCA	No	Yes	No	Yes	Pred/MMF/UDCA/Mesa
AIH	F	10.9	Asymptomatic	UC	Not	Yes	ANA 1:320; SMA 1:160; p-ANCA positive	Yes	Yes	No	Yes	Pred/UDCA/Mesa
ASC	F	16	Insidious	None	Yes	Not	ANA 1:160; p-ANCA positive	Yes	Yes	Yes	No	Pred/MMF/UDCA
ASC	M	4.3	Asymptomatic	CD	Not	Yes	ANA 1:160; SMA 1:160; p-ANCA +++	Yes	Yes	No	Yes	Pred/UDCA/Mesa
ASC	F	8.6	Insidious	UC	Not	Not	SMA 1:40; p-ANCA positive	No	No	No	Yes	Pred/AZA/UDCA/Mesa
ASC	F	12.1	Insidious	UC²	Not	Not	SMA 1:40; p-ANCA positive	No	No	No	Yes	Pred/AZA/UDCA
ASC	M	14.1	Insidious	None	Not	Not	SMA 1:40; p-ANCA positive	Yes	Yes	No	Yes	Pred/AZA/UDCA
ASC	M	14.3	Acute	UC	Not	Yes	ANA 1:320; SMA 1:320	Yes	No	No	Yes	Pred/UDCA/Mesa
ASC	F	13.8	Asymptomatic	UC	Yes	Yes	ANA 1:640; p-ANCA positive	No	Yes	Yes	Yes	Pred/MMF/UDCA/Mesa
ASC	F	5.1	Acute	IC	Not	Not	ANA 1:160; p-ANCA positive	No	Yes	No	Yes	Pred/MMF/UDCA/Mesa
ASC	F	13.1	Acute	CD	Yes	Yes	ANA 1:80; p-ANCA positive	No	Yes	No	Yes	Pred/MMF/UDCA/Mesa
ASC	F	3.6	Asymptomatic	UC	Yes	Not	ANA 1:160; SMA 1:80; p-ANCA positive	Yes	Yes	No	Yes	Pred/MMF/UDCA/Mesa

¹Spleen size detected on liver scan o magnetic resonance cholangiopancreatography.

²Patient underwent colectomy at age of 14 years.

³It includes at least one of the following: Inflammatory injury of the bile duct, ductular reaction, periductular fibrosis, biliary metaplasia, granulomatous cholangitis[16].

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; IBD: Inflammatory bowel disease; UC: Ulcerative colitis, CD: Crohn disease; IC: Indeterminate colitis; ULN: Upper limit of normal; F: Female; M: Male; ANA: Anti-nuclear antibody; SMA: Smooth muscle antibody; ANCA: Anti-neutrophil cytoplasmic antibodies; Pred: Prednisone; UDCA: Ursodeoxycholic acid; MMF: Mycophenolate mofetil; Mesa: Mesalazyne.

Table 4 Biochemical response to oral vancomycin and Sclerosing Cholangitis Outcomes in Pediatrics index score of 12 patients with autoimmune liver disease treated with oral vancomycin

Patients/diagnosis	Age at OVT (yr)	AST (NV ≤ 45 U/L)				ALT (NV ≤ 45 U/L)				GGT (NV ≤ 50 U/L)				Response to OVT ¹	SCOPE index score²		Time on OVT (mo)	OVT side-effect	Overall FU³ (mo)
Patients/diagnosis	Age at OVT (yr)	Before OVT	After OVT	TTN	Result	Before OVT	After OVT	TTN	Result	Before OVT	After OVT	TTN	Result	Response to OVT ¹	Before OVT	After OVT	Time on OVT (mo)	OVT side-effect	Overall FU³ (mo)
AIH	5.4	212	39	4 mo	NV	147	17	6 mo	NV	73	22	6 mo	NV	Complete	3 low risk	0 low risk	99	None	113
AIH	11.8	251	31	2 mo	NV	359	39	9 mo	NV	26	34	8 mo	NV	Complete	3 low risk	0 low risk	72	None	73
ASC	16.8	98	47	3 mo	< 1.5 NV	140	70	4	< 1.5 NV	39	83	4	< 1.5 NV	Partial	8 high risk	8 high risk	16	None	26
ASC	4.8	86	28	7 d	NV	156	38	14 d	NV	84	44	14 d	NV	Complete	4 medium risk	1 low risk	37	None	39
ASC	13.1	60	14	1 mo	NV	365	38	3 mo	NV	68	27	4 mo	NV	Complete	5 medium risk	2 low risk	31	None	84
ASC	15.2	71	40	14 mo	NV	140	56	14 mo	< 1.5 NV	52	164	12 mo	-	None	6 high risk	6 high risk	6	None	68
ASC	17.4	113	65	1 mo	< 1.5 NV	205	141	1 mo	-	49	226	1 mo	-	None	6 high risk	4 medium risk	3	None	52
ASC	15	407	30	6 mo	NV	856	35	6 mo	NV	61	28	1 mo	NV	Complete	5 medium risk	2 low risk	40	None	49
ASC	17.3	102	37	2 mo	NV	111	36	2 mo	NV	135	82	5 mo	< 1.5 NV	Partial	6 high risk	4 medium risk	18	None	61
ASC	12.5	76	31	2 mo	NV	124	40	7 mo	NV	86; TX	42	6 mo	NV	Complete	5 medium risk	4 medium risk	47	None	135
ASC	13.9	123	155	-	-	165	154	-	-	165	1800	-	-	None	8 high risk	8 high risk	6	None	86; TX
ASC	13.2	141	135	-	-	156	180	-	-	71 mo (range 26-165)	136	-	-	None	7 high risk	7 high risk	4	None	165
Response to OVT					10/12 (83%)				9/12 (75%)				8/12 (67%)				Median: 34 (range 1-99)		71 (range 26-165)

¹Complete response is defined as “normalization of all three liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT)]”, partial response as “AST, ALT or GGT levels decreasing to < 1.5 × ULN without reaching normal value”, and no response as “no significant changes in liver enzymes”.

²Sclerosing Cholangitis Outcomes in Pediatrics: Points 0-3: Low risk; Points 4-5: Medium risk; Points 6-11: High risk.

³Time from diagnosis to last follow up visit.

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; OVT: Oral vancomycin treatment; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; TTN: Time to normalize or to achieve the lowest value; NV: Normal value; FU: Follow up; SCOPE: Sclerosing Cholangitis Outcomes in Pediatrics.

Citation: Di Giorgio A, Tulone A, Nicastro E, Norsa L, Sonzogni A, D'Antiga L. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience. World J Hepatol 2021; 13(12): 2113-2127
URL: https://www.wjgnet.com/1948-5182/full/v13/i12/2113.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i12.2113